Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7741358
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
US8022228
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) |
Market Authorisation Date: 13 August, 2009
Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults
Dosage: TABLET;SUBLINGUAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic